ITM gains $204.6m investment for radiopharmaceutical pipeline

2024-06-07

疫苗临床3期临床2期

ITM gains $204.6m investment for radiopharmaceutical pipeline

Preview

来源: Pharmaceutical Technology

The funding will support the commercial launch of the company’s Phase III lead candidate, ITM-11, for cancer. Credit: Lightspring / Shutterstock.

ITM Isotope Technologies Munich (ITM) has secured an investment of €188m ($204.6m) aimed at bolstering its radiopharmaceutical pipeline.

Recommended Buyer's Guides

Preview

来源: Pharmaceutical Technology

Buyer's Guide

Leading Guide to Compliance Software for the Pharmaceutical Industry

Preview

来源: Pharmaceutical Technology

Buyer's Guide

Leading Guide to Clinical Packaging Companies in contract Manufacturing for the Pharmaceutical Industry

Global investment company Temasek spearheaded the funding round with contributions from entities managed by BlackRock, the Qatar Investment Authority (QIA), ATHOS and Carbyne.

The funding will be channelled towards advancing and broadening ITM’s radiopharmaceutical pipeline, supporting the development platform and commercially launching its Phase III lead candidate, ITM-11 (n.c.a.177Lu-edotreotide).

The asset is currently under evaluation in two Phase III trials, COMPETE and COMPOSE, for the treatment of gastroenteropancreatic neuroendocrine tumours.

The investment will enable ITM to bolster its manufacturing capabilities for Lutetium-177 (177Lu) and expand its production to include other high-value medical radioisotopes such as Actinium-225 (225Ac).

See Also:FDA recommends updated Covid-19 vaccines Covid-19 vaccines targeting JN.1

Preview

来源: Pharmaceutical Technology

India’s DCGI approves Orchid Pharma’s API Enmetazobactam

Preview

来源: Pharmaceutical Technology

As part of the expansion, the company will also supply the in-demand medical radioisotopes to its extensive global network and utilise them to diversify its radiopharmaceutical therapy pipeline. This strategy is designed to address a variety of challenging cancer indications.

ITM CEO Steffen Schuster stated: “The additional equity and continued collaboration with our existing, industry-specialised investors emphasises their confidence in our ability to drive value for the radiopharmaceutical field through our unmatched manufacturing capabilities and innovative precision oncology pipeline.

“We have reached key milestones since our last financing round including advancing our pipeline with novel targets in multiple oncology indications, opening our NOVA facility, launching Actineer with CNL for the joint production of Actinium-225 and entering several high-value supply agreements for Lutetium-177.

“As we continue growing as an organisation, our focus remains on bringing the significant therapeutic benefits of radiopharmaceutical therapy to as many patients worldwide as possible and we are thankful for the additional financing which will support us on this path.”

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构